China Medical System profit up 3.1% in H1

Revenue increased 10.8% to $715.2m

China Medical System Holdings reported a net profit of $166.5m (RMB931.5m) for the six months ended 30 June 2025, up 3.1% from $161.5m (RMB903.4m) in the same period last year.

Revenue increased 10.8% to $715.2m (RMB4,002m). If all medicines were sold directly by the group, turnover would have risen 8.9% to $834.8m (RMB4,669.6m).

Basic earnings per share grew 4.2% to $0.0695 (RMB0.3892), compared with $0.0667 (RMB0.3734) in H1 2024.

As of 30 June 2025, the group held $617.5m (RMB3,454.1m) in cash and bank balances, with $31.9m (RMB178.6m) in readily realisable bank acceptance bills.

The board declared an interim dividend of $0.0278 per share (RMB0.1555), up 3.2% from $0.0269 (RMB0.1507) in H1 2024.

The board said the solid profit growth reflects CMS’s continued focus on operational efficiency and sustainable expansion in the healthcare sector.